Cancer immunotherapy: Phase II clinical studies with TG4010 (MVA-MUC1-IL2)

Journal of B.U.ON.

Volumn 12, Issue SUPPL. 1, 2007, Pages

  Acres, Bruce ^a  

^a TRANSGENE S A   (France)

Author keywords

Cancer vaccine; Immune monitoring; Immunotherapy; Lung cancer; MUC1; MVA

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER TESTIS ANTIGEN; CANCER VACCINE; CISPLATIN; CYTOKINE; FETAL ANTIGEN; INTERLEUKIN 2; MUCIN 1; NAVELBINE; PROSTATE SPECIFIC ANTIGEN; SMALLPOX VACCINE; SORAFENIB; TG 1013; TG 1031; TG 4010; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

AUTOIMMUNITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FLU LIKE SYNDROME; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; KIDNEY CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTE ACTIVATION; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PROSTATE CANCER; SURVIVAL RATE; SURVIVAL TIME; VACCINIA VIRUS; VARIABLE NUMBER OF TANDEM REPEAT;

BREAST NEOPLASMS; CA-15-3 ANTIGEN; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASMS; POXVIRIDAE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 36749007179     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Matzinger P. The danger model: a renewed sense of self Science 2002; 296: 301-305.
2. Ohlen C, Kalos M, Hong DJ, Shur AC, Greenberg PD. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen. J Immunol 2001; 166: 2863-2870.
3. Scholl S, Squiban P, Bizouarne N et al. Metastatic breast tumour regression following treatment by a gene modified vaccinia virus expressing MUC1 and IL2. J Biomed Biotech 2003; 3: 194-201.
4. Banu E, Linassier C, Rixe O et al. A phase II study of the cancer immunotherapy vaccine TG4010 alone and in combination with cytokines in patients with metastatic RCC. J Clin Oncol 2006; 24 (Suppl): 18S, 2581 (abstr). (manuscript in preparation).
5. Velu T, Ramlau R, Quoix E et al. A phase II study evaluating the clinical efficacy of TG4010 (MVA-MUC1-IL2) in association with chemotherapy in patients with Non Small Cell Lung Cancer. J Clin Oncol 2005; 23 (Suppl): 16S, 7132 (abstr). (manuscript in preparation).
6. Franzke A, Peest D, Probst-Kepper M et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 1999; 17: 529-533.
7. Acres B, Limacher J-M. MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 2005; 4: 493-502.
8. Stacker SA, Tjandra JJ, Xing PX, Walker ID, Thompson CH, McKenzie IF. Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3e1.2. Br J Cancer 1989; 59: 544-553.
9. Keydar I, Chou CS, Hareuveni M et al. Production and characterization of monoclonal antibodies identifying breast tumor-associated antigens. Proc Natl Acad Sci USA 1989; 86: 1362-1366.
10. Burchell J, Gendler S, Taylor-Papadimitriou J et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987; 47: 5476-5482.
11. Wajchman HJ, Pierce CW, Varma, VA, Issa MM, Petros J, Dombrowski KE. Ex vivo expansion of CD8+CD56+ and CD8+CD56- natural killer T cells specific for MUC1 mucin. Cancer Res 2004; 64: 1171-1180.
12. Jerome KR, Barnd DL, Bendt KM et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma, recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991; 51: 2908-2916.
13. Brossart P, Wirths S, Stuhler G, Reichardt V L, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96: 3102-3108.
14. Scholl SM, Balloul JM, Le Goc G et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 2000; 23: 570-580.
15. Pantuck AJ, van Ophoven A, Gitlitz BJ et al. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother 2004; 27: 240-253.
16. Scholl S, Squiban P, Bizouarne N et al. Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2. J Biomed Biotechnol 2003; 3: 194-201.
17. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl) Dtsch Med Wochenschr 1974; 99: 2386-2392.
18. Rochlitz C, Figlin R, Squiban P et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003; 5: 690-699.
19. Dreicer R, Ahmann FR, Pantuck AJ et al. NWA-MUC1-IL2 vaccine immunotherapy (TG4010) in patients with prostate cancer with biochemical failure. J Clin Oncol 2005; 23 (Suppl): 16S, 4518 (abstr). (manuscript in preparation).